High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database

Gregory A. Abel; Ann Vanderplas; Maria A. Rodriguez; Allison L. Crosby; Myron S. Czuczman; Joyce C. Niland; Leo I. Gordon; Michael Millenson; Andrew D. Zelenetz; Jonathan W. Friedberg; Ann S. Lacasce

doi:10.3109/10428194.2011.639882

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database

Gregory A. Abel^*, Ann Vanderplas, Maria A. Rodriguez, Allison L. Crosby, Myron S. Czuczman, Joyce C. Niland, Leo I. Gordon, Michael Millenson, Andrew D. Zelenetz, Jonathan W. Friedberg, Ann S. Lacasce

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

We aimed to characterize surveillance imaging and circumstances of relapse for patients with diffuse large B-cell lymphoma (DLBCL) in the National Comprehensive Cancer Network Non-Hodgkin's Lymphoma Outcomes Database, a prospective cohort study collecting clinical and outcome data at seven comprehensive cancer centers. Patients presenting with newly diagnosed DLBCL in remission ≥3 months after initial therapy and who had accrued 2 years of follow-up were eligible for analysis (n 625). The median number of imaging studies was 2.5/year (institutional range 0.53.5, p < 0.0001); 48.4% received only dedicated computed tomography (CT) scans, 14.6% received only positron emission tomography (PET)-inclusive modalities, 32.8% received a combination and 4.2% received no imaging. Among all eligible patients, 50 (8.0%) experienced relapse, and approximately one-quarter of subclinical relapses were detected through routine imaging. Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up.

Original language	English (US)
Pages (from-to)	1113-1116
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	53
Issue number	6
DOIs	https://doi.org/10.3109/10428194.2011.639882
State	Published - Jun 2012

Keywords

Diagnostic imaging
Diffuse large B-cell lymphoma
Health services research

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2011.639882

Fingerprint Dive into the research topics of 'High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database'. Together they form a unique fingerprint.

Cite this

Abel, G. A., Vanderplas, A., Rodriguez, M. A., Crosby, A. L., Czuczman, M. S., Niland, J. C., Gordon, L. I., Millenson, M., Zelenetz, A. D., Friedberg, J. W., & Lacasce, A. S. (2012). High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database. Leukemia and Lymphoma, 53(6), 1113-1116. https://doi.org/10.3109/10428194.2011.639882

Abel, Gregory A. ; Vanderplas, Ann ; Rodriguez, Maria A. ; Crosby, Allison L. ; Czuczman, Myron S. ; Niland, Joyce C. ; Gordon, Leo I. ; Millenson, Michael ; Zelenetz, Andrew D. ; Friedberg, Jonathan W. ; Lacasce, Ann S. / High rates of surveillance imaging for treated diffuse large B-cell lymphoma : Findings from a large national database. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 6. pp. 1113-1116.

@article{8b203fd8f54d424f8946194635eceef5,

title = "High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database",

abstract = "We aimed to characterize surveillance imaging and circumstances of relapse for patients with diffuse large B-cell lymphoma (DLBCL) in the National Comprehensive Cancer Network Non-Hodgkin's Lymphoma Outcomes Database, a prospective cohort study collecting clinical and outcome data at seven comprehensive cancer centers. Patients presenting with newly diagnosed DLBCL in remission ≥3 months after initial therapy and who had accrued 2 years of follow-up were eligible for analysis (n 625). The median number of imaging studies was 2.5/year (institutional range 0.53.5, p < 0.0001); 48.4% received only dedicated computed tomography (CT) scans, 14.6% received only positron emission tomography (PET)-inclusive modalities, 32.8% received a combination and 4.2% received no imaging. Among all eligible patients, 50 (8.0%) experienced relapse, and approximately one-quarter of subclinical relapses were detected through routine imaging. Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up.",

keywords = "Diagnostic imaging, Diffuse large B-cell lymphoma, Health services research",

author = "Abel, {Gregory A.} and Ann Vanderplas and Rodriguez, {Maria A.} and Crosby, {Allison L.} and Czuczman, {Myron S.} and Niland, {Joyce C.} and Gordon, {Leo I.} and Michael Millenson and Zelenetz, {Andrew D.} and Friedberg, {Jonathan W.} and Lacasce, {Ann S.}",

year = "2012",

month = jun,

doi = "10.3109/10428194.2011.639882",

language = "English (US)",

volume = "53",

pages = "1113--1116",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "6",

}

Abel, GA, Vanderplas, A, Rodriguez, MA, Crosby, AL, Czuczman, MS, Niland, JC, Gordon, LI, Millenson, M, Zelenetz, AD, Friedberg, JW & Lacasce, AS 2012, 'High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database', Leukemia and Lymphoma, vol. 53, no. 6, pp. 1113-1116. https://doi.org/10.3109/10428194.2011.639882

High rates of surveillance imaging for treated diffuse large B-cell lymphoma : Findings from a large national database. / Abel, Gregory A.; Vanderplas, Ann; Rodriguez, Maria A.; Crosby, Allison L.; Czuczman, Myron S.; Niland, Joyce C.; Gordon, Leo I.; Millenson, Michael; Zelenetz, Andrew D.; Friedberg, Jonathan W.; Lacasce, Ann S.

In: Leukemia and Lymphoma, Vol. 53, No. 6, 06.2012, p. 1113-1116.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - High rates of surveillance imaging for treated diffuse large B-cell lymphoma

T2 - Findings from a large national database

AU - Abel, Gregory A.

AU - Vanderplas, Ann

AU - Rodriguez, Maria A.

AU - Crosby, Allison L.

AU - Czuczman, Myron S.

AU - Niland, Joyce C.

AU - Gordon, Leo I.

AU - Millenson, Michael

AU - Zelenetz, Andrew D.

AU - Friedberg, Jonathan W.

AU - Lacasce, Ann S.

PY - 2012/6

Y1 - 2012/6

N2 - We aimed to characterize surveillance imaging and circumstances of relapse for patients with diffuse large B-cell lymphoma (DLBCL) in the National Comprehensive Cancer Network Non-Hodgkin's Lymphoma Outcomes Database, a prospective cohort study collecting clinical and outcome data at seven comprehensive cancer centers. Patients presenting with newly diagnosed DLBCL in remission ≥3 months after initial therapy and who had accrued 2 years of follow-up were eligible for analysis (n 625). The median number of imaging studies was 2.5/year (institutional range 0.53.5, p < 0.0001); 48.4% received only dedicated computed tomography (CT) scans, 14.6% received only positron emission tomography (PET)-inclusive modalities, 32.8% received a combination and 4.2% received no imaging. Among all eligible patients, 50 (8.0%) experienced relapse, and approximately one-quarter of subclinical relapses were detected through routine imaging. Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up.

AB - We aimed to characterize surveillance imaging and circumstances of relapse for patients with diffuse large B-cell lymphoma (DLBCL) in the National Comprehensive Cancer Network Non-Hodgkin's Lymphoma Outcomes Database, a prospective cohort study collecting clinical and outcome data at seven comprehensive cancer centers. Patients presenting with newly diagnosed DLBCL in remission ≥3 months after initial therapy and who had accrued 2 years of follow-up were eligible for analysis (n 625). The median number of imaging studies was 2.5/year (institutional range 0.53.5, p < 0.0001); 48.4% received only dedicated computed tomography (CT) scans, 14.6% received only positron emission tomography (PET)-inclusive modalities, 32.8% received a combination and 4.2% received no imaging. Among all eligible patients, 50 (8.0%) experienced relapse, and approximately one-quarter of subclinical relapses were detected through routine imaging. Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up.

KW - Diagnostic imaging

KW - Diffuse large B-cell lymphoma

KW - Health services research

UR - http://www.scopus.com/inward/record.url?scp=84861379630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861379630&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.639882

DO - 10.3109/10428194.2011.639882

M3 - Article

C2 - 22098406

AN - SCOPUS:84861379630

VL - 53

SP - 1113

EP - 1116

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -